(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/074143 A1

(51) International Patent Classification:
C07D 239/70 (2006.01) *A61K 31/505* (2006.01)
C07D 413/12 (2006.01) *A61K 31/517* (2006.01)
C07D 495/04 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2021/077757

(22) International Filing Date:
07 October 2021 (07.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

20200850.4	08 October 2020 (08.10.2020)	EP
20213590.1	11 December 2020 (11.12.2020)	EP
21165054.4	25 March 2021 (25.03.2021)	EP

(71) Applicant: **BASILEA PHARMACEUTICA INTERNATIONAL AG** [CH/CH]; Grenzacherstrasse 487, 4058 Basel (CH).

(72) Inventors: **WEILER, Sven**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH). **GAUCHER, Bérangère**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH). **RICHALET, Florian**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH). **REINELT, Stefan**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH). **RADIMERSKI, Thomas**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH). **ALOIA, Andrea**; Basilea Pharmaceutica International AG Grenzacherstrasse 487, 4058 Basel (CH).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER



(57) Abstract: The invention provides compounds of formula (IA) and compounds of formula (IB) and pharmaceutically acceptable salts thereof; wherein A is selected from group (A1) and group (A2): wherein #1 is attached to the carbon atom forming the oxime moiety and wherein group (A1) is optionally substituted by one or two R10 and group (A2) is optionally substituted by one R10, and wherein R1, X, R2 and R10 are as defined in the claims, as well as methods of using the compounds to treat neoplastic diseases, in particular cancer.

WO 2022/074143 A1